Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-care

Current biopharmaceutical manufacturing systems are not compatible with portable or distributed production of biologics, as they typically require the development of single biologic-producing cell lines followed by their cultivation at very large scales. Therefore, it remains challenging to treat patients in short time frames, especially in remote locations with limited infrastructure. To overcome these barriers, we developed a platform using genetically engineered Pichia pastoris strains designed to secrete multiple proteins on programmable cues in an integrated, benchtop, millilitre-scale microfluidic device. We use this platform for rapid and switchable production of two biologics from a single yeast strain as specified by the operator. Our results demonstrate selectable and near-single-dose production of these biologics in <24 h with limited infrastructure requirements. We envision that combining this system with analytical, purification and polishing technologies could lead to a small-scale, portable and fully integrated personal biomanufacturing platform that could advance disease treatment at point-of-care.

[1]  Heike Sieber,et al.  Strain and process development for the production of human cytokines in Hansenula polymorpha. , 2002, FEMS yeast research.

[2]  William Crown,et al.  Melding regulatory, pharmaceutical industry, and U.S. payer perspectives on improving approaches to heterogeneity of treatment effect in research and practice. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  Roland Contreras,et al.  Modification of the N-glycosylation pathway to produce homogeneous, human-like glycans using GlycoSwitch plasmids. , 2007, Methods in molecular biology.

[4]  Bernhard Diel,et al.  Flexible Biomanufacturing Processes that Address the Needs of the Future. , 2014, Advances in biochemical engineering/biotechnology.

[5]  Daniel Cummings,et al.  Integrated continuous production of recombinant therapeutic proteins , 2012, Biotechnology and bioengineering.

[6]  Michael Sauer,et al.  Recombinant protein production in yeasts. , 2012, Methods in molecular biology.

[7]  Rajeev J Ram,et al.  Plastic-PDMS bonding for high pressure hydrolytically stable active microfluidics. , 2009, Lab on a chip.

[8]  Ahmad S. Khalil,et al.  A Synthetic Biology Framework for Programming Eukaryotic Transcription Functions , 2012, Cell.

[9]  Timothy K Lu,et al.  Synthetic circuits integrating logic and memory in living cells , 2013, Nature Biotechnology.

[10]  Kurt Brorson,et al.  The need for innovation in biomanufacturing , 2012, Nature Biotechnology.

[11]  Barry Lennox,et al.  The development of an industrial-scale fed-batch fermentation simulation. , 2015, Journal of biotechnology.

[12]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[13]  J. Cregg,et al.  Heterologous protein expression in the methylotrophic yeast Pichia pastoris. , 2000, FEMS microbiology reviews.

[14]  Brigitte Gasser,et al.  Induction without methanol: novel regulated promoters enable high-level expression in Pichia pastoris , 2013, Microbial Cell Factories.

[15]  K. Thiel,et al.  Biomanufacturing, from bust to boom...to bubble? , 2004, Nature Biotechnology.

[16]  S Subramani,et al.  The CUP1 promoter of Saccharomyces cerevisiae is inducible by copper in Pichia pastoris , 2000, Yeast.

[17]  Rajeev J Ram,et al.  Microfluidic chemostat and turbidostat with flow rate, oxygen, and temperature control for dynamic continuous culture. , 2011, Lab on a chip.

[18]  B. Strukelj,et al.  Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells , 2013, Journal of Industrial Microbiology & Biotechnology.

[19]  Charles A. Gersbach,et al.  Light-Inducible Spatiotemporal Control of Gene Activation by Customizable Zinc Finger Transcription Factors , 2012, Journal of the American Chemical Society.

[20]  Anton Glieder,et al.  New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris , 2013, Current opinion in biotechnology.

[21]  Teresa Mitchell,et al.  Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study , 2011, mAbs.

[22]  Shigeyuki Yamaguchi,et al.  A Method for Producing Transgenic Cells Using a Multi-Integrase System on a Human Artificial Chromosome Vector , 2011, PloS one.

[23]  Alan Dove,et al.  Uncorking the biomanufacturing bottleneck , 2002, Nature Biotechnology.

[24]  M. Vidal,et al.  Sequence and chromosomal context effects on variegated expression of keratin 5/lacZ constructs in stratified epithelia of transgenic mice. , 2001, Genetics.

[25]  T. Hwang,et al.  Stock Market Returns and Clinical Trial Results of Investigational Compounds: An Event Study Analysis of Large Biopharmaceutical Companies , 2013, PloS one.

[26]  Harry L. T. Lee,et al.  A perfusion-capable microfluidic bioreactor for assessing microbial heterologous protein production. , 2015, Lab on a chip.

[27]  Farshid Guilak,et al.  Synergistic and tunable human gene activation by combinations of synthetic transcription factors , 2013, Nature Methods.

[28]  Jianwei Zhu,et al.  Mammalian cell protein expression for biopharmaceutical production. , 2012, Biotechnology advances.

[29]  Benjamin L. Oakes,et al.  Synthetic gene expression perturbation systems with rapid, tunable, single-gene specificity in yeast , 2012, Nucleic acids research.

[30]  L. Harvey,et al.  Heterologous protein production using the Pichia pastoris expression system , 2005, Yeast.

[31]  Roland Contreras,et al.  In Vivo Synthesis of Mammalian-Like, Hybrid-Type N-Glycans in Pichia pastoris , 2004, Applied and Environmental Microbiology.

[32]  Suzanne S Farid,et al.  Capacity Planning for Batch and Perfusion Bioprocesses Across Multiple Biopharmaceutical Facilities , 2014, Biotechnology progress.

[33]  C D Day,et al.  Transgene integration into the same chromosome location can produce alleles that express at a predictable level, or alleles that are differentially silenced. , 2000, Genes & development.

[34]  Francisco Valero,et al.  Developing high cell density fed-batch cultivation strategies for heterologous protein production in Pichia pastoris using the nitrogen source-regulated FLD1 Promoter. , 2005, Biotechnology and bioengineering.

[35]  Heidi Ledford.  First biosimilar drug set to enter US market , 2015, Nature.

[36]  Byung-Kwon Choi,et al.  Generation of diploid Pichia pastoris strains by mating and their application for recombinant protein production , 2012, Microbial Cell Factories.

[37]  Ye Zhang,et al.  Very High Density of CHO Cells in Perfusion by ATF or TFF in WAVE Bioreactor™. Part I. Effect of the Cell Density on the Process , 2013, Biotechnology progress.

[38]  Suzanne S Farid,et al.  Continuous bioprocessing: The real thing this time? , 2014, mAbs.

[39]  Lei Yang,et al.  Permanent genetic memory with >1 byte capacity , 2014, Nature Methods.

[40]  David Pollard,et al.  A review of advanced small‐scale parallel bioreactor technology for accelerated process development: Current state and future need , 2011, Biotechnology progress.